Last reviewed · How we verify
Clopidogrel plus ASA
Clopidogrel and aspirin together inhibit platelet aggregation through complementary pathways to prevent thrombotic events.
Clopidogrel and aspirin together inhibit platelet aggregation through complementary pathways to prevent thrombotic events. Used for Acute coronary syndrome, Percutaneous coronary intervention with stent placement, Secondary prevention of cardiovascular events.
At a glance
| Generic name | Clopidogrel plus ASA |
|---|---|
| Also known as | Clopidogrel plus aspirin |
| Sponsor | University of Athens |
| Drug class | Dual antiplatelet agent |
| Target | P2Y12 receptor (clopidogrel); cyclooxygenase (aspirin) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Clopidogrel is a P2Y12 receptor antagonist that blocks ADP-induced platelet activation, while aspirin irreversibly inhibits cyclooxygenase to prevent thromboxane A2 production. Combined dual antiplatelet therapy (DAPT) provides synergistic inhibition of platelet function through two distinct mechanisms, reducing the risk of stent thrombosis and recurrent ischemic events.
Approved indications
- Acute coronary syndrome
- Percutaneous coronary intervention with stent placement
- Secondary prevention of cardiovascular events
Common side effects
- Bleeding
- Dyspepsia
- Gastrointestinal hemorrhage
- Rash
- Thrombotic thrombocytopenic purpura (TTP)
Key clinical trials
- The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis (PHASE4)
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
- Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia (PHASE4)
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
- SIMPLAAFY Clinical Trial (NA)
- Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe (CATIS- ICAS) (PHASE3)
- STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clopidogrel plus ASA CI brief — competitive landscape report
- Clopidogrel plus ASA updates RSS · CI watch RSS
- University of Athens portfolio CI